Literature DB >> 10882396

5-HT(1A) receptor agonist-antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems.

J Watson1, L Collin, M Ho, G Riley, C Scott, J V Selkirk, G W Price.   

Abstract

1. It has been reported that radiolabelled agonist : antagonist binding affinity ratios can predict functional efficacy at several different receptors. This study investigates whether this prediction is true for recombinant and native tissue 5-HT(1A) receptors. 2. Saturation studies using [(3)H]-8-OH-DPAT and [(3)H]-MPPF revealed a single, high affinity site (K(D)approximately 1 nM) in HEK293 cells expressing human 5-HT(1A) receptors and rat cortex. In recombinant cells, [(3)H]-MPPF labelled 3 - 4 fold more sites than [(3)H]-8-OH-DPAT suggesting the presence of more than one affinity state of the receptor. [(3)H]-Spiperone labelled a single, lower affinity site in HEK293 cells expressing h5-HT(1A) receptors but did not bind to native tissue 5-HT(1A) receptors. These data suggest that, in transfected HEK293 cells, human 5-HT(1A) receptors exist in different affinity states but in native rat cortical tissue the majority of receptors appear to exist in the high agonist affinity state. 3. Receptor agonists inhibited [(3)H]-MPPF binding from recombinant 5-HT(1A) receptors in a biphasic manner, whereas antagonists and partial agonists gave monophasic inhibition curves. All compounds displaced [(3)H]-8-OH-DPAT and [(3)H]-spiperone binding in a monophasic manner. In rat cortex, all compounds displaced [(3)H]-MPPF and [(3)H]-8-OH-DPAT in a monophasic manner. 4. Functional evaluation of compounds, using [(35)S]-GTPgammaS binding, produced a range of intrinsic activities from full agonism, displayed by 5-HT and 5-CT to inverse agonism displayed by spiperone. 5. [(3)H]-8-OH-DPAT : [(3)H]-MPPF pK(i) difference correlated well with functional intrinsic activity (r=0.86) as did [(3)H]-8-OH-DPAT : [(3)H]-spiperone pK(i) difference with functional intrinsic activity (r=0.96). 6. Thus agonist : antagonist binding affinity differences may be used to predict functional efficacy at human 5-HT(1A) receptors expressed in HEK293 cells where both high and low agonist affinity states are present but not at native rat cortical 5-HT(1A) receptors in which only the high agonist affinity state was detectable.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882396      PMCID: PMC1572157          DOI: 10.1038/sj.bjp.0703394

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Species differences in the distribution of central 5-HT1 binding sites: a comparative autoradiographic study between rat and guinea pig.

Authors:  H Sijbesma; J Schipper; J C Cornelissen; E R de Kloet
Journal:  Brain Res       Date:  1991-08-02       Impact factor: 3.252

2.  Relative affinities of drugs acting at cholinoceptors in displacing agonist and antagonist radioligands: the NMS/Oxo-M ratio as an index of efficacy at cortical muscarinic receptors.

Authors:  S B Freedman; E A Harley; L L Iversen
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

3.  Correlation between low/high affinity ratios for 5-HT(1A) receptors and intrinsic activity.

Authors:  M B Assié; C Cosi; W Koek
Journal:  Eur J Pharmacol       Date:  1999-12-10       Impact factor: 4.432

4.  The character of the muscarinic receptors in different regions of the rat brain.

Authors:  N J Birdsall; E C Hulme; A Burgen
Journal:  Proc R Soc Lond B Biol Sci       Date:  1980-02-13

5.  The binding of agonists to brain muscarinic receptors.

Authors:  N J Birdsall; A S Burgen; E C Hulme
Journal:  Mol Pharmacol       Date:  1978-09       Impact factor: 4.436

6.  A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor.

Authors:  A De Lean; J M Stadel; R J Lefkowitz
Journal:  J Biol Chem       Date:  1980-08-10       Impact factor: 5.157

7.  Evaluation of an agonist index: affinity ratio for compounds active on muscarinic cholinergic M2 receptors.

Authors:  S K Tayebati; A Piergentili; D Natale; F Amenta
Journal:  J Auton Pharmacol       Date:  1999-04

8.  Differential regulation of high-affinity agonist binding to muscarinic sites in the rat heart, cerebellum, and cerebral cortex.

Authors:  T W Vickroy; H I Yamamura; W R Roeske
Journal:  Biochem Biophys Res Commun       Date:  1983-10-14       Impact factor: 3.575

9.  A1 adenosine receptor-G protein coupling in bovine brain membranes: effects of guanine nucleotides, salt, and solubilization.

Authors:  G L Stiles
Journal:  J Neurochem       Date:  1988-11       Impact factor: 5.372

10.  Pharmacological characterisation of the 5-HT1A serotonin receptor using the agonist [3H]8-OH-DPAT, and the antagonist [3H]spiperone.

Authors:  H Sundaram; A Newman-Tancredi; P G Strange
Journal:  Biochem Soc Trans       Date:  1992-05       Impact factor: 5.407

View more
  15 in total

1.  SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue.

Authors:  J Watson; C Roberts; C Scott; I Kendall; L Collin; N C Day; M H Harries; E Soffin; C H Davies; A D Randall; T Heightman; L Gaster; P Wyman; C Parker; G W Price; D N Middlemiss
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

Review 2.  PET tracers for serotonin receptors and their applications.

Authors:  J S Dileep Kumar; J John Mann
Journal:  Cent Nerv Syst Agents Med Chem       Date:  2014

3.  Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors.

Authors:  Martyn Wood; Vanessa Dubois; Dieter Scheller; Michel Gillard
Journal:  Br J Pharmacol       Date:  2015-01-13       Impact factor: 8.739

4.  Differential modulation by GTPgammaS of agonist and inverse agonist binding to h5-HT(1A) receptors revealed by [3H]-WAY100,635.

Authors:  A Newman-Tancredi; L Verrièle; M J Millan
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

5.  Analysis of molecular determinants of affinity and relative efficacy of a series of R- and S-2-(dipropylamino)tetralins at the 5-HT1A serotonin receptor.

Authors:  J Tracy Alder; Uli Hacksell; Philip G Strange
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 6.  Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

Authors:  Victor W Pike
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 7.  Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.

Authors:  Lee A Dawson; Jeannette M Watson
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243

8.  Alpha 2A-adrenoceptor-specific stimulation of [35S]GTP gamma S binding to membrane preparations of rat frontal cortex.

Authors:  Oliver Pulges; Ago Rinken
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

9.  Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl- 11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione in nonhuman primates.

Authors:  J S Dileep Kumar; Jaya Prabhakaran; Vattoly J Majo; Matthew S Milak; Shu-Chi Hsiung; Hadassah Tamir; Norman R Simpson; Ronald L Van Heertum; J John Mann; Ramin V Parsey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-13       Impact factor: 10.057

10.  DSP-1053, a novel serotonin reuptake inhibitor with 5-HT1A partial agonistic activity, displays fast antidepressant effect with minimal undesirable effects in juvenile rats.

Authors:  Taro Kato; Yuji Matsumoto; Masanori Yamamoto; Kenji Matsumoto; Satoko Baba; Keiko Nakamichi; Harumi Matsuda; Haruka Nishimuta; Kazuki Yabuuchi
Journal:  Pharmacol Res Perspect       Date:  2015-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.